Dr. Muhammad Rizvi, MD

Dr. Rizvi practices at Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University.

Dr. Rizvi's NPI, 1346277555, was assigned on June 26, 2006. Dr. Rizvi graduated from Dow University of Health Sciences in 2001. Dr. Rizvi holds Pennsylvania license MD449290.

Dr. Rizvi's primary practice is Lehigh Valley Hospital-Cedar Crest, at 1200 South Cedar Crest Boulevard, Allentown, PA 18103 in Lehigh County. The practice phone is (610) 402-8000.

Dr. Rizvi's primary practice is Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University. Dr. Rizvi is also affiliated with St. Luke's University Hospital - Bethlehem Campus. The medical group on file is Lehigh Valley Physician Group (LVPG). Dmand AI also links Dr. Rizvi to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rizvi practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Rizvi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Rizvi's licenses on file in 2 states: Pennsylvania and Massachusetts.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances, immune deficiency disease and lung cancer among the conditions Dr. Rizvi treats.

CMS data shows 1,010 Medicare services from Dr. Rizvi across 6 procedure codes in 2024, for 330 Medicare patients. Medicare paid $69,968 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 330 Medicare patients who saw Dr. Rizvi in 2024. The largest group is 65 to 74, with 152 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rizvi's median patient age at 68, with 70% women.

In 2024, Dr. Rizvi wrote 1,172 Medicare Part D claims for 260 patients. 82% of them were for generic drugs. CMS names the drug for 1,018 of them, across 29 drugs with 11 or more claims each, at $1,688,017 in total drug cost. In 2023, CMS named 1,127 claims across 29 drugs.

Dr. Rizvi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rizvi as offering telehealth.

Dmand AI links 12 papers to Dr. Rizvi, published from 2019 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Myocarditis. Dr. Rizvi has published most often in Cureus. Dr. Rizvi's most frequent co-authors are Gagan Deep Sahni, MD, Sarju B. Ganatra, MD and Dipti Gupta, MD, MPH.

CMS Open Payments shows 108 general payments to Dr. Rizvi from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,910.

Dr. Rizvi graduated from Dow University of Health Sciences in 2001.

Dr. Rizvi is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.